
|
 |
Tuberculosis Genotyping Project, United States
Identifying the Sources of
Tuberculosis in Young Children: A Multistate Investigation
Sumi J. Sun,* Diane E. Bennett, Jennifer
Flood,* Ann M. Loeffler,* Steve Kammerer, and Barbara A. Ellis
*California Department of Health
Services, Berkeley, California, USA; and Centers for Disease Control and
Prevention, Atlanta, Georgia, USA
Suggested citation for this article: Sun SJ,
Bennett DE, Flood J, Loeffler AM, Kammerer S, Ellis BA. Identifying the
sources of tuberculosis in young children: a multistate investigation.
Emerg Infect Dis [serial online] 2002 Nov [date cited];8. Available from:
URL: http://www.cdc.gov/ncidod/EID/vol8no11/02-0419.htm
To
better understand the molecular epidemiology of tuberculosis (TB)
transmission for culture-confirmed patients <5 years of age, data were
analyzed from a population-based study conducted in seven U.S. sites from
1996 to 2000. Mycobacterium tuberculosis isolates were genotyped
with IS6110-based restriction fragment length polymorphism analysis
and spoligotyping. Case-patient data were obtained from the Centers for
Disease Control and Preventions national tuberculosis registry and health
department records. Routine public health investigations conducted by
local health departments identified suspected source patients for 57 (51%)
of 111 culture-confirmed patients <5 years of age. For 8 (15%) of 52
culture-confirmed patients <5 years of age and their suspected source
patients with complete genotyping results, genotypes suggested infection
with different TB strains. Potential differences between sources for
patients <5 years of age and source patients that transmitted TB to
adolescent and adult patients were identified.
The occurrence of tuberculosis (TB) in children is
an indicator of ongoing Mycobacterium tuberculosis transmission and
of deficiencies in current public health efforts. In the United States,
strategies to prevent childhood TB include identifying and promptly
initiating treatment for adults with active TB to interrupt transmission (14).
Since children have an increased risk for developing severe disease within
weeks to months of infection, they are high priorities when identified as
contacts to infectious patients (5,6).For newly diagnosed
TB in children, source-case investigations are conducted to ascertain the
source of infection and to prevent ongoing transmission from infectious
persons. Despite efforts by TB-control programs, suboptimal numbers of
source patients are identified for children (712).
Pinpointing the source of TB infection may be particularly challenging when
numerous exposures exist, including contact with persons who reside outside
the United States (13). Failure to find the true source
patient may have treatment implications; decisions about the treatment
regimen for children often hinge on the drug-susceptibility results of the
suspected source patient because cultures from young children are often not
available or attempts are not made to obtain these cultures (14).
The use of molecular analysis with conventional epidemiology has increased
our understanding of TB transmission (15,16).
In outbreaks and population-based studies, genotyping has been instrumental
in identifying previously unsuspected connections among TB patients (17).
Genotyping has also been used to evaluate epidemiologic links established
through contact investigations. One report found that more than one quarter
of index patients and their contacts who had TB and shared a household were
infected with different TB strains, indicating that transmission did not
occur between the household contacts (18). In 1996, the
Centers for Disease Control and Prevention (CDC) established the National
Tuberculosis Genotyping and Surveillance Network (genotyping network) to
conduct population-based genotyping in seven U.S. sentinel surveillance
sites (19). During a 5-year period, the network collected
information on culture-confirmed patients and their contacts with TB who
were identified through routine public health investigations. Study sites
also attempted to collect and genotype at least one M. tuberculosis
isolate from each reported culture-confirmed case in the surveillance area.
To better understand the molecular epidemiology of TB transmission among
young children (patients <5 years of age), data collected by the genotyping
network were analyzed to report the frequency that suspected source patients
were identified for young children, to examine the frequency and
characteristics of source patients for young children, and to determine the
proportion of isolates from young children and their identified source
patients with discordant genotypes. We also investigated potential
differences in the characteristics of source patients who transmitted TB to
young children as compared to source patients who transmitted to adolescent
and adult patients.
Methods
Collection of
Epidemiologic Data
A detailed description of study participants,
population, and methodology is reported elsewhere (20). In
brief, health department records were reviewed for all culture-confirmed
patients who met the surveillance case definition (21) and
were reported from the seven sites (Arkansas, California [six counties],
Maryland, Massachusetts, Michigan, New Jersey, and Texas [four counties])
from January 1996 through December 2000. Contacts (of culture-confirmed
patients in the sentinel areas) with active TB were identified through
routine public health investigations, as defined by local contact and
source-case investigation policies and practices at each study site. Source
case investigations were undertaken for all patients <5 years of age. Two
sites also routinely performed source case investigations on children ³5
years of age. Information about epidemiologically related patients
identified from public health investigations was gathered with a
standardized data collection form that included the direction of
transmission (i.e., whether the contact was a source patient or secondary
patient in relation to the index patient or whether the direction of
transmission was unknown), the relationship between patients (shared a
household, nonhousehold friends or relatives, co-worker, or common source),
and the exposure setting (correctional, school or day-care center,
workplace, emergency shelter, group quarters, hospital, nursing home, other
long-term care facility, or other setting). Data were entered into Epi Info
version 6d (22) databases and routinely sent to CDC. State
TB registry numbers for patients in the multisite genotyping network
database were matched against the CDCs national TB surveillance registry to
obtain sociodemographic, behavioral, clinical, treatment, and
drug-susceptibility information, which is routinely reported for all TB
patients on the Report of Verified Patients of Tuberculosis (23).
Project activities described in this paper were determined by CDCs
institutional review board to be exempt from full committee review since
genotyping of isolates was considered a public health surveillance activity
and all other data used in the analysis of this paper were previously
collected.
Genotyping of M. tuberculosis isolates was
conducted in accordance with standardized study protocols (20).
IS6110-based restriction fragment length polymorphism (RFLP) analysis
was performed on all available isolates. Because low-copy numbers of IS6110
reduce test specificity, isolates containing six or fewer IS6110
copies were further analyzed by spacer oligonucleotide typing (spoligotyping)
(24). Patients were determined to have concordant
genotypes if their isolates contained seven or more IS6110 bands with
identical patterns or six or fewer IS6110 bands with identical
patterns and matching spoligotypes.
Study Case
Definitions
Our investigation focused on culture-confirmed
patients <5 years of age; TB in young children represents recent
transmission, and source patient investigations are routinely conducted for
this group. A source patient was defined as a confirmed TB patient who was
identified by chart abstraction as the likely source of infection for
another reported TB patient. A secondary patient was defined as a confirmed
TB patient who was infected by an identifiable source. Epidemiologically
related source patients and secondary patients identified through routine
public health investigations were considered suspected patient pairs.
Because some source patients transmitted TB to more than one secondary
patient, the number of suspected patient pairs does not equal the number of
source patients. A secondary patient, however, could have only one
designated source patient.
Genotypes for isolates from suspected patient pairs
were compared, and patient pairs were categorized as 1) confirmed patient
pairs, if isolates had concordant genotypes 2) refuted patient pairs, if
isolates had discordant genotypes, and 3) undetermined patient pairs, if
genotypes were unavailable for the patient pair.
Data in the multisite genotyping network database
were analyzed with SAS version 8.0 (25) and Epi Info
version 6d (22) software packages. Patients were excluded
from analysis when records were not available for review or lacked complete
information from public health investigations, including three patients <5
years of age from one site, for whom source patients were not identified but
who were entered into the database as the source for an adult case. Because
young children are not typically considered to be infectious (26)
and records for these patients were not available for further examination at
the time of this analysis, information was determined to be incomplete for
these patients.
Univariate analysis was conducted to examine factors
associated with the identification of source patients for young children and
to investigate associations between key variables and the identification of
refuted patient pairs. Differences in proportions were assessed with the
chi-square statistic or 2-tailed Fisher exact test. Relative risks (RR) and
95% confidence intervals of point estimates were generated where
appropriate. Differences in the means of continuous data were tested with
the Wilcoxon rank-sum test when sample sizes were small. Unless otherwise
noted, p values <0.05 were interpreted as statistically significant
differences for all statistical tests.
Genotypes of isolates from young children without a
known source patient were matched against the genotyping network project
database to find previously unidentified adult TB patient(s) whose genotype
matched the childs. Since the sentinel study sites represented
geographically dispersed states that did not necessarily share a common
border, genotype matches were limited to patients from the same site.
To better describe the unique characteristics of
patients who transmit TB to young children, source patients (in confirmed
patient pairs) who transmitted TB to young children were compared with those
who transmitted to adolescents or adult patients. Since source patients who
infected children 5 years of age or older may be very similar to source
patients who infected children newly born to 4 years of age, two different
comparison groups were identified 1) source patients for all secondary
patients >5 years of age and 2) source patients for secondary
patients >15 years of age (excluding source patients that transmitted
to children 514 years of age).
Characteristics of Children with TB
From 1996 to 2000, a total of 15,035 TB patients
were reported from the seven sentinel surveillance sites; 11,923 (79%) were
culture confirmed, and isolates from 10,752 (90%) culture-confirmed patients
were genotyped. Of all patients in the study, 518 (3%) patients were <5
years of age. Culture was attempted in 270 (52%) patients <5 years of age,
and 122 (45%) of these patients were culture confirmed. Isolates from 114
(93%) culture-confirmed children <5 years of age were genotyped.
Texas and California sites reported 73 (60%) of
the 122 culture-confirmed patients <5 years of age; the Michigan and New
Jersey sites reported 18 patients each, and the remaining three sites
reported £6 patients each. Most (65%) of the study patients were <2 years of
age, and 49% were girls. Forty-three percent were black, non-Hispanic; 37%
Hispanic; 15% Asian; 4% white, non-Hispanic, and 2% Native-American or
Alaskan Native. Of the 11 foreign-born patients <5 years of age, 4 were from
Mexico, 2 were from Kenya, and 5 were from other countries. Two thirds of
the young children had pulmonary TB disease, 15% had extrapulmonary disease,
and 20% had both pulmonary and extrapulmonary TB.
With some notable exceptions, culture-confirmed
patients <5 years of age had demographic or clinical characteristics similar
to those of the 396 young children from the surveillance area who were
either culture-negative or did not have a specimen collected for culture.
The culture-confirmed group was more likely to be £1 year old (RR=1.94,
p=<0.001); whereas white, non-Hispanic children (RR=0.41, p=0.02) and those
treated only by private providers (RR=0.6, p=0.002) were underrepresented in
the sample of culture-confirmed patients.
Results of routine investigations used in
identifying source patients for culture-confirmed children <5 years of age
are presented in Figure 1. Health department records
were unavailable or lacked sufficient information about investigations of 11
patients; these records were excluded. At least one epidemiologically
related case was identified for 66 (59%) young children with
culture-confirmed TB; 57 (86%) patients had a source patient designated, but
a source could not be determined for the remaining 9 patients, although an
epidemiologically related case was identified. For five of the nine
patients, multiple epidemiologically related patients (ranging from 211
related patients) were identified.
To examine factors associated with the
identification of source patients for culture-confirmed children <5 years of
age, we compared young children with a suspected source patient to patients
with an unknown source of infection (Table 1).
Children <2 years of age were more likely to have a source patient
identified from routine public health investigations; however, source
patients were less frequently found for foreign-born children. No other
statistically significant differences were found. Drug-susceptibility
patterns for isolates from young children with any drug resistance are
detailed in Table 2.
Table 3 lists characteristics of
the 53 source patients identified from public health investigations. In 41
(72%) of 57 suspected patient pairs involving young children, the source
patient lived in the childs household. Of the 16 nonhousehold sources, 3
were babysitters, 4 were neighbors or visitors, 2 were relatives, and 1
attended the same church as the childs family; the specific relationship
was unknown for 6 patient pairs. Eight (15%) of the source patients resulted
in disease in more than one young child (including culture-negative children
and patients outside of the study population).
Of the 57 culture-confirmed patients <5 years of
age for whom a source patient was identified, 91% (52) had
genotyping results for both the young child and the suspected source patient
(Figure 2). Forty-four (85%) of 52 suspected patient
pairs had concordant genotypes, and 8 (15%) of 52 had discordant genotypes.
Young children in refuted patient pairs were more likely to be older than
those in confirmed patient pairs (Table 4). No
association between gender, ethnicity, or foreign-born status of patients
and the identification of refuted patient pairs was found. Nearly three
quarters (37 of 52) of suspected patient pairs lived in the same household;
however, 5 (14%) of these patient pairs had discordant genotypes. Suspected
patient pairs with differing drug-susceptibilities were not associated with
discordant genotypes; all three patient pairs with differing drug resistance
patterns had concordant genotypes (Table 5).
For the nine young patients who had at least one
epidemiologically related patient identified by public health investigations
but for whom the source patient could not be determined, genotyping patterns
from the isolates of the epidemiologically related cases and the young child
were identical, almost without exception. The only two discordant genotypes
were in young children with a single related case, not among the five young
children with multiple related patients.
Genotyping also identified patients in the local
surveillance site who had the same genotype as young children without an
identified source patient. Isolates were genotyped from 40 of 45 patients <5
years of age without a known source patient. Of these genotyped isolates, 23
(58%) matched the strain from at least l adult pulmonary TB case in the
local surveillance site. For most young children (13 [57%] of 23) without an
identified source patient, at least 5 adult pulmonary TB patients with
genotypes matching the childs were identified. We found a wide range in the
number of adult patients (2128) with genotypes matching the genotypes of
these young children.
To better characterize the unique attributes of
patients who transmit TB to young children, characteristics of their source
patients (in confirmed patient pairs) were compared with those for adults
and adolescents. No significant differences were found when the comparison
group for this analysis consisted of all sources to secondary patients ³5
years of age or when the comparison group was limited to sources to
secondary patients ³15 years of age. The results of the latter comparison
are presented. More than 60% (354 of 584) of the suspected patient pairs in
which the secondary patient was not a child were genotyped, and 240 (68%) of
these patient pairs had concordant genotypes (Figure 2).
The likelihood of identifying patient pairs with discordant genotypes was
more than two times higher among suspected patient pairs involving secondary
patients ³15 years of age than for those involving young children (32% vs.
15% discordant genotypes) (RR=2.09, p=0.01).
Univariate associations between source patient
characteristics and transmission to young children were assessed (Table
6). Although the mean age for sources to secondary patients <5 years of
age was slightly lower than the mean age of sources to the comparison group,
these differences were not significant (p=0.06; Wilcoxon test). For this
population, confirmed source patients to young children were more likely to
be foreign-born (p=0.02), Hispanic (p<0.001), a household member (p<0.001),
and not receiving directly observed therapy (p<0.01) as compared with
sources for adolescents and adults.
Discussion
Despite the continued decline in the number of TB
patients in the United States, ongoing TB transmission persists in many
communities. For public health agencies, TB in young children signals recent
transmission and missed opportunities for TB prevention. In this
investigation, molecular tools were used in conjunction with information
from conventional public health investigations to better understand issues
related to the identification of source patients for young children.
In this multisite study, 57 (51%) of 111
culture-confirmed patients <5 years of age had a source patient identified
by routine investigations. Although this finding is comparable to the
frequency of source patient identification reported for other subpopulations
of children with TB (8,1011),
the finding may be lower than anticipated for a sample of young children
predominantly born in the United States. Children <2 years of age and
those born in the United States were more likely to have a source patient
found than children without these characteristics. These results
corroborated findings from a study of children <5 years of age with TB in
California, which demonstrated that the source of infection is more likely
to be identified for children who were found in a contact investigation,
born in the United States, <1 year of age, or black (9).
Children <5 years of age with an unknown source of
infection composed a substantial proportion of the study population (41%), a
finding that underscores shortcomings in identifying all contacts of
infectious patients. While molecular data alone are not enough to prove
recent transmission, the presence of infectious TB patients in the community
who share the same strain with a young child without a known source suggests
the possibility of casual transmission. Other impediments in identifying
source patients may include barriers in completing contact investigations,
delays in evaluation, and problems in identifying source patients who reside
outside the health departments jurisdiction (27).
Eighty-four percent of young children without a source patient in this study
were born in the United States; this observation is likely to underestimate
the contribution of the global TB epidemic, because TB surveillance systems
in the United States do not routinely monitor the birthplace or travel
history of parents or guardians, factors previously identified as
significant predictors for pediatric TB (28,29).
Of particular concern is the finding that 16 (14%)
of 111 culture-confirmed young children had more than one
epidemiologically related TB source identified. This finding indicates that
a substantial number of children have multiple TB exposures that need to be
carefully assessed. For most, the source of infection was ascertained and
later confirmed by genotyping analysis. When multiple epidemiologically
related patients existed, but none was identified as the source patient,
genotyping analysis did not provide added benefit since the related patients
were more likely to have the same genotype.
Clinicians and TB-control programs often rely on the
drug-susceptibility results of the suspected source patient to guide the
treatment of the child since specimens for culture are not frequently
collected from children (14). Previous studies by Steiner
et al. reported 93% to 96% concordance of drug-susceptibility patterns of TB
isolates from children <15 years of age and their source (30,31),
comparable to the 93% drug-susceptibility concordance among suspected
patient pairs in our study population. All suspected patient pairs with
discordant drug-susceptibility results were among patient pairs with
concordant genotypes, indicating the value of drug-susceptibility results in
young children, even when genotyping results are known to the local health
department.
The high frequency (85%) of concordant genotypes among
young children and their source patients represents good news for public
health agencies; when a potential source of infection was identified in this
population, it was most often accurate. However, for as many as 15%, the
true source was not identified and presumably could have contributed to the
further spread of disease in the community. Because young children may have
more limited opportunities for exposure than older children, we anticipated
that the frequency of confirmed patient pairs would be associated with young
age. We also speculated that foreign-born children, especially those from
high TB-prevalence areas, might have an increased risk of being involved in
a refuted patient-pair. These children might have had multiple opportunities
for exposure to active TB before entering the United States, which may
increase the possibility that the source of infection could have been
someone other than the suspected source patient. However, this potential
association could not be assessed because our sample of foreign-born
children with culture-confirmed TB was small.
The increased likelihood of concordant genotypes among
suspected patient pairs involving young children as compared with suspected
patient pairs that did not include children (85% vs. 68%) may be explained
by a number of factors, including the greater number of casual contacts with
whom adults interact, biases in the case-finding practices for these groups,
and potential for coincidental reactivation of a latent TB infection in
older patient pairs. Source patients who transmitted TB to young children
were more likely to be Hispanic, foreign-born, a household member, and not
receiving directly observed therapy as compared to sources for adolescents
or adults. The latter may indicate nonadherence of source patients to drug
treatment and corroborates an observation by Kimerling et al. (32).
However, additional data are needed to determine the confounding factors,
including site-to-site variance, that may affect which source patients
receive directly observed therapy, as discussed in the limitations that
follow.
A key limitation in this study was the inability to
assess the effect of potential confounding factors, such as differences in
case-finding methods (i.e., if patients were identified through contact
investigation, source patient investigations, or screening activities) on
the outcome of interest (i.e., identification of source patients or
confirmed patient pairs). These data represented the sites routine public
health practices and policies, since uniform policies for public health
investigations were not instituted, and potential systematic variances
across sites were not ascertained by the project. In addition, analysis of
epidemiologic investigations for infectious patients in the community who
shared the same TB strain as the young child but were not identified from
public health investigators was outside the scope of this paper. A follow-up
investigation to find epidemiologic connections among patients currently
linked by genotyping results alone may provide important data regarding
potential missed opportunities in this group. Finally, the predictive value
of a discordant genotype result is not yet known. Although study protocols
instituted quality-control measures across genotyping laboratories, a subset
of isolates from suspected patient pairs who were determined to have
discordant genotypes might include TB strains that are potentially the same.
Thus, the proportion of discordance observed in this study may represent an
overestimate of the actual frequency of suspected patient pairs with
discordant genotypes.
This study highlights the challenges in identifying
the sources of infection for culture-confirmed children under 5 years of age
and potential weakness in our current TB-control and prevention practices in
this population. Although contact and source patient investigations are
central to any TB-control strategy, the usefulness of these activities in
identifying the true source of infection in young children has not been
previously evaluated for a large population of children by using molecular
methods. While indicating a high degree of concordance between genotypes
from young children and their identified sources, genotyping analysis also
refuted some source patients and pointed to other potential sources in the
community who were previously unsuspected. Further assessment of
shortcomings in current methods to prevent transmission to children and to
identify their source of infection is warranted to ultimately eliminate TB
in young children in the United States.
The authors thank Chris Braden and Scott McNabb for
scientific guidance and for overseeing the genotyping network project,
Marisa Moore for supplying data from the Centers for Disease Control and
Preventions national TB registry, and all participants of the genotyping
network for their efforts to ensure the success of the project.
This work was supported by the Centers for Disease
Control and Prevention through funds for the genotyping network.
Ms. Sun is a research
scientist in the Surveillance and Epidemiology Section of the California
Tuberculosis Control Branch.
References
- American Thoracic Society.
Control of tuberculosis in the United States. Am Rev Respir Dis
1992;146:162333.
- Perry S, Starke JR. Adherence to prescribed treatment and public
health aspects of tuberculosis in children. Seminars in Pediatric
Infectious Diseases 1993;4:2918.
- Centers for Disease Control and Prevention. Screening for tuberculosis
and tuberculosis infection in high-risk populations: recommendations of
the Advisory Council for the Elimination of Tuberculosis. MMWR Morb Mortal
Wkly Rep 1995;44:1934.
- Centers for Disease Control and Prevention.
Essential components of a tuberculosis prevention and control program:
recommendations of the Advisory Council for the Elimination of
Tuberculosis. MMWR Morb Mortal Wkly Rep 1995;44:116.
- Fujiwara PI, editor. Clinical policies and protocols. New York: New
York City Department of Health, Bureau of Tuberculosis Control; 1999. p.
937.
- Marshman FC, editor. Prevention and control of pediatric tuberculosis
in New York City: recommendation for the expert advisory panel. New York:
New York City Department of Health; 1995. p. 189.
- Driver CR, Luallen JJ, Good WE, Valway SE, Frieden TR, Onorato IM.
Tuberculosis in children younger than five years of age: New York City.
Pediatr Infect Dis J 1995;14:1127.
- Gessner BD.
Incidence rates, clinical features, and case identification of pediatric
tuberculosis in Alaska. Int J Tuberc Lung Dis 1998;2:37883.
- Lobato MN, Mohle-Boetani JC, Royce SE.
Missed opportunities for preventing tuberculosis among children younger
than five years of age. Pediatrics 2000;106:E75.
- Lobato MN, Loeffler AM, Furst K, Cole B, Hopewell PC.
Detection of Mycobacterium tuberculosis in gastric aspirates
collected from children: hospitalization is not necessary. Pediatrics
1998;102:E40.
- Moss W.
Tuberculosis in the home: contact history and childhood tuberculosis in
central Harlem. Clin Pediatr (Phila) 1998;37:7535.
- Watchi R, Kahlstrom E, Vachon LA, Barnes PF.
Pediatric tuberculosis: clinical presentation and contact investigation at
an urban medical center. Respiration 1998;65:1924.
- Sullam PM, Slutkin G, Hopewell PC.
The benefits of evaluating close associates of child tuberculin reactors
from a high prevalence group. Am J Public Health 1986;76:110911.
- Al-Dossary F, Ong L, Correa A, Starke JR.
Treatment of childhood tuberculosis with a six month directly observed
regimen of only two weeks daily therapy. Pediatr Infect Dis J
2002;21:912
- Jasmer RM, Hahn JA, Small PM, Daley CL, Behr MA, Moss AR, et al.
A molecular epidemiologic analysis of tuberculosis trends in San
Francisco, 19911997. Ann Intern Med 1999;130:9718.
- Behr MA, Warren SA, Salamon H, Hopewell PC, Ponce de Leon A, Daley CL,
et al.
Transmission of Mycobacterium tuberculosis from patients
smear-negative for acid-fast bacilli. Lancet 1999;353:4449.
- Chin DP, Crane CM, Diul MY, Sun SJ, Agraz R, Taylor S, et al.
Spread of Mycobacterium tuberculosis in a community implementing
recommended elements of tuberculosis control. JAMA 2000;283:296874.
- Behr MA, Hopewell PC, Paz EA, Kawamura LM, Schecter GF, Small PM.
Predictive value of contact investigation for identifying recent
transmission of Mycobacterium tuberculosis. Am J Respir Crit
Care Med 1998;158:4659.
- Castro KG, Jaffe HW. Rationale and methods for the National
Tuberculosis Genotyping and Surveillance Network. Emerg Infect Dis
2002;8: (this issue)
- Crawford JT, Braden CR, Schable BA. National tuberculosis genotyping
and surveillance network: designs and methods. Emerg Infect Dis 2002;8:
(this issue)
- Centers for Disease Control and Prevention. Case definitions for
public health surveillance. MMWR Morb Mortal Wkly Rep 1990;39:3940.
- Epi Info: a word processing, database, and statistics program
[computer program]. Version 6. Atlanta: Centers for Disease Control and
Prevention; 1994.
- Centers for Disease Control and Prevention. Tuberculosis information
management system (TIMS) users guide. Surveillance appendix 1. Atlanta:
U.S. Department of Health Services, Public Health Service; 1999.
- Bauer J, Andersen AB, Kremer K, Miorner H.
Usefulness of spoligotyping to discriminate IS6110 low-copy-number
Mycobacterium tuberculosis complex strains cultured in Denmark. J
Clin Microbiol 1999;37:26026.
- SAS/STAT users guide. Cary (NC): SAS Institute Inc.; 2000.
- A statement of the Scientific Committee of the IUATLD. Tuberculosis in
children: guidelines for diagnosis, prevention, and treatment. Bull Int
Union Tuberc Lung Dis 1991;66:1149.
- Besser RE, Pakiz B, Schulte JM, Alvarado S, Zell ER, Kenyon TA, et al.
Risk factors for positive mantoux tuberculin skin tests in children in San
Diego, California: evidence for boosting and possible foodborne
transmission. Pediatrics 108:30510.
- Kenyon TA, Driver C, Haas E, Valway SE, Moser KS, Onorato IM.
Immigration and tuberculosis among children on the United States-Mexico
border, County of San Diego, California. Pediatrics 1999;104:E8.
- Saiman L, San Gabriel P, Schulte J, Vargas MP, Kenyon T, Onorato I.
Risk factors for latent tuberculosis infection among children in New York
City. Pediatrics 2001;107:9991003.
- Steiner M, Zimmerman R, Park BH, Shirali SR, Schmidt IT.
Primary tuberculosis in children: II. Correlation of susceptibility
patterns of Mycobacterium tuberculosis isolated from children with
those isolated from source cases as an index of drug resistant infection
in a community. Am Rev Respir Dis 1968;98:2019.
- Steiner P, Rao M, Mitchell M, Steiner M. Primary drug-resistant
tuberculosis in children.
Correlation of drug-susceptibility patterns of matched patient and source
case strains of Mycobacterium tuberculosis. Am J Dis Child
1985;139:7802.
- Kimerling ME, Vaughn ES, Dunlap NE.
Childhood tuberculosis in Alabama: epidemiology of disease and indicators
of program effectiveness, 1983 to 1993. Pediatr Infect Dis J
1995;14:67884.
| Table 1.
Factors associated with identifying source patients for
culture-confirmed tuberculosis in children <5 years of agea |
|
|
Characteristics |
Suspected sources identified n=57 (%) |
No suspected source identified n=45 (%) |
Relative risk (95% CI) |
p value |
|
| Age <2
yrsb |
44 |
(77) |
20 |
(45) |
1.96 (1.23 to 3.12) |
0.001 |
| Female |
30 |
(53) |
21 |
(47) |
|
NS |
|
Race/ethnicity |
|
|
|
|
|
NS |
| Black,
non-Hispanic |
26 |
(46) |
19 |
(42) |
|
|
|
Hispanic |
23 |
(40) |
12 |
(27) |
|
|
| Asian |
5 |
(9) |
11 |
(24) |
|
|
| White,
non-Hispanic |
1 |
(2) |
3 |
(7) |
|
|
| Native
American or Alaskan Native |
2 |
(4) |
0 |
(0) |
|
|
| Foreign-bornc |
1 |
(2) |
7 |
(16) |
0.21 (0.03 to 1.31) |
0.02 |
|
|
|
|
|
|
|
NS |
|
|
40 |
(70) |
30 |
(67) |
|
|
|
|
5 |
(9) |
8 |
(18) |
|
|
|
|
12 |
(21) |
7 |
(16) |
|
|
| Provider typed |
|
|
|
|
|
NS |
| Health
department |
17 |
(31) |
10 |
(23) |
|
|
| Private
provider |
18 |
(33) |
21 |
(49) |
|
|
| Both |
20 |
(36) |
12 |
(28) |
|
|
| Directly
observed therapye |
46 |
(85) |
28 |
(68) |
|
NS |
|
Drug-resistant isolatef |
6 |
(11) |
8 |
(16) |
|
NS |
|
aNS,
not significant; CI, confidence interval.
bAge at start of treatment. Excludes one child whose date of
treatment was unknown.
cExcludes one child whose birthplace was unknown.
dExcludes four children whose provider type was
unknown.
eCompared to patients on self-administered therapy.
fDrug resistance on initial testing of isolate; resistance to
at least one of the following: isoniazid, rifampin, ethambutol,
pyrazinamide, streptomycin, and ethionamide. Testing results for one or
more drugs could have been unknown or not done. Excludes two children
for whom drug-susceptibility testing was not done. |
| Table 2.
Drug-susceptibility patterns for isolates from culture-confirmed
patients <5 years of age with and without a suspected source patient
identifieda |
|
| Suspected
source patient identified |
Source patient not identified |
|
| Ethionamide |
Isoniazid |
| Streptomycin |
Streptomycin |
| Streptomycin |
Streptomycin |
| Isonazid,
streptomycin |
Pyrazinamide |
| Isonazid,
streptomycin |
Pyrazinamide |
| Isonazid,
rifampin, ethambutol streptomycin |
Isoniazid, streptomycin |
| |
Isoniazid, rifampin |
| |
Isoniazid, ethambutol, streptomycin |
|
| aThrough
routine public health investigations. |
| |
| Table 3.
Demographic, clinical, and risk characteristics of 53 source
patients with tuberculosis (TB) identified from public health
investigationsa |
|
| Source
patient characteristics |
|
|
| Age group,
yrs |
|
| 1524 |
11 (21) |
| 2544 |
28 (53) |
| 4564 |
10 (19) |
| 65+ |
4 (8) |
| Female |
24 (45) |
| Race or
ethnicity |
|
| Black,
non-Hispanic |
22 (42) |
|
Hispanic |
24 (45) |
| Asian |
5 (9) |
| Native
American or Alaskan Native |
2 (4) |
| Foreign-bornb |
27 (51) |
| Bacteriologic
results, sputum |
|
| Smear
positive/culture positive |
42 (79) |
| Smear
positive/culture negative |
1 (2) |
| Smear
negative/culture positive |
8 (15) |
| Smear
not done/culture not done |
2 (4) |
| Cavitary
chest radiographc |
33 (63) |
| Provider type |
|
| Health
department |
31 (58) |
| Private
provider |
11 (11) |
| Both |
11 (11) |
| Directly
observed therapyd |
47 (71) |
| Previous
diagnosis of TB |
5 (9) |
|
Drug-resistant isolatee |
5 (9) |
|
aThree
source patients were identified as the source of infection for more than
one culture-confirmed patient who was <5 years of age in the sentinel
study population; two source patients transmitted to two
children, and one transmitted to three children.
bCountry of origin was Mexico for 14 (26%) of the foreign-born
patients.
cResults unknown for one patient.
dCompared to patients on self-administered therapy.
eDrug resistance on initial testing of isolate; resistance to at
least one of the following: isoniazid, rifampin, ethambutol,
pyrazinamide, streptomycin, and ethionamide. Testing results for one or
more drugs could have been unknown or not done. Excludes one source
patient for whom drug susceptibility testing was not done. |
| Table 4.
Characteristics of refuted and confirmed patients pairsa
|
|
| |
Refuted patient pairs
n=8 (%) |
Confirmed patient pairs
n=44 (%) |
|
|
Characteristics of young children |
| Mean
age, monthsb |
16 |
13 |
|
Female |
4 (50) |
23 (52) |
|
Race/ethnicity |
|
|
|
Black, non-Hispanic |
5 (63) |
20 (45) |
|
Hispanic |
3 (38) |
16 (36) |
|
Asian |
0 (0) |
5 (11) |
|
White, non-Hispanic |
0 (0) |
1 (2) |
|
Native American/Alaskan Native |
0 (0) |
2 (5) |
|
Foreign-born |
1 (13) |
0 (0) |
|
Source patient characteristics |
| Mean
age, yrs |
25 |
31 |
|
Female |
6 (75) |
18 (41) |
| Race
or ethnicity |
|
|
|
Black, non-Hispanic |
5 (63) |
20 (45) |
|
Hispanic |
3 (38) |
17 (39) |
|
Asian |
0 (0) |
5 (11) |
|
Native American or Alaskan Native |
0 (0) |
2 (5) |
|
Foreign-born |
3 (38) |
20 (45) |
|
|
|
Shared household |
5 (63) |
32 (73) |
|
Discordant drug susceptibilitiesc |
0 (0) |
|
|
Different race/ethnicity |
0 (0) |
1 (2) |
|
aFor
tuberculosis patients <5 years of age and their suspected source
patients. Refuted patient pairs are suspected patient pairs with
discordant genotypes; confirmed patient pairs are suspected patient
pairs with concordant genotypes.
bWilcoxon rank-sum test: p=0.03.
cExcludes two patient pairs in which the children had
drug-resistant Mycobacterium tuberculosis strains
(streptomycin and ethambutol resistance, respectively), but
susceptibility results were not done for the identified source patient.
|
| Table 5.
Comparison of drug-susceptibility and genotyping results for isolates of
suspected patient pairsa with any drug resistance |
|
|
Source-patient isolate |
Secondary patient isolate
(children <5 years of age) |
Drug-susceptibility comparison
(patient pairs) |
Genotype
comparison
(patient pairs) |
|
| Isoniazid |
Isoniazid, streptomycin |
Discordant |
Concordant |
| Isoniazid,
rifampin |
|
Discordant |
Concordant |
| Streptomycin |
Pan-susceptible |
Discordant |
Concordant |
| Streptomycin |
Streptomycin |
Concordant |
Concordant |
| Isoniazid,
streptomycin |
Isoniazid, streptomycin |
Concordant |
Concordant |
| Pan-susceptibleb |
Ethionamide |
Undeterminedc |
Concordant |
| Not done |
Streptomycin |
Undetermined |
Undetermined |
|
aTuberculosis
patients <5 years of age and their suspected source patients.
bIsolate from source patient was not tested for ethionamide
resistance.
cUndetermined, results unknown for one or both patients.
|
| Table 6.
Characteristics of source patients in confirmed patient pairsa |
|
| Source
patient characteristics |
Confirmed sources for secondary
patients <5 yrs of age
n=44 (%) |
Confirmed sources for secondary
patients ≥15 ys of age
n=240 (%) |
|
| Mean age, yrs |
31 |
38 |
| Female |
18 (41) |
103 (43) |
| Race/ethnicityb |
|
|
|
Black, non-Hispanic |
20 (45) |
148 (62) |
|
Hispanic |
17 (39) |
23 (10) |
| Asian |
5 (11) |
19 (8) |
|
White, non-Hispanic |
0 |
48 (20) |
|
Native American or Alaskan Native |
2 (5) |
2 (1) |
| Foreign-bornc |
20 (45) |
56 (23) |
| Bacteriologic
results, sputumd |
|
|
| Smear
positive/culture positive |
34 (81) |
200 (85) |
| Smear
negative/culture positive |
8 (19) |
33 (14) |
| Smear
negative/culture negative |
0 |
1 (<1) |
| Cavitary
chest radiographe |
27 (64) |
125 (53) |
| Provider typef |
|
|
|
Health department |
25 (57) |
141 (60) |
|
Private provider |
9 (20) |
|
| Both |
10 (23) |
52 (22) |
| Directly
observed therapy b,g |
30 (68) |
198 (84) |
| Previous
diagnosis of TBh |
6 (14) |
27 (11) |
| Shared
household with secondary case b,i |
32 (91) |
116 (50) |
|
aConfirmed
patient pairs include source patients who transmitted TB to young
children and source patients who transmitted TB to adolescent and adult
patients.
bChi-square statistic, p<0.05.
cCountry of origin unknown for one patient.
dExcludes eight patients in whom either the culture or smear was
not done.
eChest radiograph results unknown for two patients.
fProvider type unknown for four patients.
gCompared to patients on self-administered therapy only. Directly
observed therapy status unknown for six patients.
hHistory of TB unknown for two patients.
iRelationship to secondary case unknown for 19 patients.
|
|